Protective Effects of Hesperidin Against Amyloid-β (Aβ) Induced Neurotoxicity Through the Voltage Dependent Anion Channel 1 (VDAC1)-Mediated Mitochondrial Apoptotic Pathway in PC12 Cells

Wang, Dong-Mei; Li, San-Qiang; Zhu, Xiao-Ying; Wang, Yong; Wu, Wen-Lan; Zhang, Xiao-Juan
May 2013
Neurochemical Research;May2013, Vol. 38 Issue 5, p1034
Academic Journal
Amyloid-β (Aβ) is known to exert cytotoxic effects by inducing mitochondrial dysfunction. Additionally, the mitochondrial voltage-dependent anion channel 1 (VDAC1), which is involved in the release of apoptotic proteins with possible relevance in Alzheimer's disease (AD) neuropathology, plays an important role in maintaining mitochondrial function and integrity. However, the application of therapeutic drugs, especially natural products in (AD) therapy via VDAC1-regulated mitochondrial apoptotic pathway has not aroused extensive attention. In the present study, we investigated neuroprotective effects of hesperidin, a bioactive flavonoid compound, on Aβ-induced neurotoxicity in PC12 cells and also examined the potential cellular signalling mechanism. Our results showed that treatment with hesperidin significantly inhibited Aβ-induced apoptosis by reversing Aβ-induced mitochondrial dysfunction, including the mitochondrial permeability transition pore opening, intracellular free calcium increase and reactive oxygen species production. Further study indicated that hesperidin can increase the level of VDAC1 phosphorylation through enhancing the activity of the glycogen synthasekinase-3β and decrease the level of hexokinaseI in mitochondrial, resulting in mitochondrial release of cytochrome c. Furthermore, hesperidin inhibited mitochondria-dependent downstream caspase-mediated apoptotic pathway, such as that involving caspase-9 and caspase-3. These results demonstrate that hesperidin can protect Aβ-induced neurotoxicity via VDAC1-regulated mitochondrial apoptotic pathway, and they raise the possibility that hesperidin could be developed into a clinically valuable treatment for AD and other neuronal degenerative diseases associated with mitochondrial dysfunction.


Related Articles

  • Research brief: Osteoarthritis treatment preferences.  // GP: General Practitioner;3/15/2004, p11 

    Researchers of Great Britain examined the treatment preferences of patients with osteoarthritis, mostly aged between 61 and 80 years. They found that the older respondents were more willing to accept an increased risk of serious side-effects to experience an improvement in symptoms.

  • Ranibizumab.  // Reactions Weekly;9/29/2007, Issue 1171, p23 

    The article presents a case study of a 70-year old man who has developed retinal pigment epithelial tear following intravitreal administration of ranibizumab for occult choroidal neovascularisation with pigment epithelial detachment due to age-related macular degeneration. Two months after...

  • Amiodarone-induced neurotoxicity. Willis, Mina S.; Lugo, Amy M. // American Journal of Health-System Pharmacy;3/15/2009, Vol. 66 Issue 6, p567 

    Purpose. A case of amiodarone-induced neurotoxicity is reported. Summary. A 76-year-old man arrived at the emergency department with complaints of increasing imbalance over the past 2.5 months after a recent discharge from the hospital. He reported that his balance had worsened over the past...

  • Cefepime.  // Reactions Weekly;4/5/2008, Issue 1196, p11 

    The article describes the cases of eight patients with renal impairment, aged between 49 and 84 years old, who developed neurotoxicity during treatment with cefepime and subsequently died. The patients developed coma and myoclonus agitation and aphasia, confusion, chorea-athetosis, convulsions...

  • Colistin/tobramycin interaction.  // Reactions Weekly;Aug2015, Vol. 1564 Issue 1, p60 

    The article presents case studies of a 31-year old man and 33-year old woman who developed neurotoxicity during treatment with colistin.

  • Colchicine interaction.  // Reactions Weekly;10/8/2005, Issue 1072, p9 

    Presents a case report of an interaction with concomitant verapamil leading to tetraparesis in an elderly patient following self-administration of colchicine. Medical history; Other medications received by the patient; Results of laboratory investigations.

  • JAUNDICE IN A PATIENT RECEIVING ZOXAZOLAMINE (FLEXIN). Jasper, Harry // American Journal of Gastroenterology;Oct1960, Vol. 34 Issue 4, p419 

    Describes a case report of an elderly patient who developed jaundice while on treatment with Zoxazolamine. Drug dosage being taken by the patient; Length of drug use; Disease symptoms observed in the patient.

  • Antipsychotics for Behavioural and Psychological Problems in Elderly People with Dementia: A Systematic Review of Adverse Events. van Iersel, Marianne B.; Zuidema, Sytse U.; Koopmans, Raymond T. C. M.; Verhey, Frans R. J.; Rikkert, Marcel G. M. Olde // Drugs & Aging;2005, Vol. 22 Issue 10, p845 

    Objective: Although antipsychotics are important in the treatment of behavioural and psychological symptoms of dementia (BPSD), they have moderate efficacy and often cause adverse events. Recent safety warnings about increased frequency of cerebrovascular adverse events in elderly patients who...

  • A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus Goldstandard Schmucker, Christine; Ehlken, Christoph; Agostini, Hansjuergen T.; Antes, Gerd; Ruecker, Gerta; Lelgemann, Monika; Loke, Yoon K. // PLoS Clinical Trials;Aug2012, Vol. 7 Issue 8, p1 

    Background: We set out a systemic review to evaluate whether off-label bevacizumab is as safe as licensed ranibizumab, and whether bevacizumab can be justifiably offered to patients as a treatment for age-related macular degeneration with robust evidence of no differential risk. Methods...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics